首页 › 非小细胞肺癌 › 得克萨斯州 › Fort Worth
Fort Worth TX 非小细胞肺癌临床试验
18项针对 非小细胞肺癌的研究正在 Fort Worth及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- The Center For Cancer And Blood Disorders, Fort Worth
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
招募中2 期
- START Fort Worth, Fort Worth
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Texas Oncology - DFW, Fort Worth
- The Center for Cancer and Blood Disorders, Fort Worth
- The Center for Cancer and Blood Disorders, Burleson · 距离 13 英里
- 以及另外 1 项
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Texas Oncology - DFW, Fort Worth
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- The Center for Cancer and Blood Disorders, Fort Worth
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Fort Worth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Fort Worth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Start Dfw, Fort Worth
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- JPS Health Network, Fort Worth
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
招募中1 期
- Texas Oncology - DFW, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
招募中2 期
- Start Ccbd, Llc, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
招募中1 期
- START Dallas, Fort Worth
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Fort Worth的其他研究
- 卵巢癌17 项研究
- 子宫内膜癌12 项研究
- 乳腺癌12 项研究
- 癌症（所有类型）9 项研究
- 前列腺癌9 项研究
- 三阴性乳腺癌7 项研究
- 黄斑变性7 项研究
- 溃疡性结肠炎7 项研究
- 肾癌（肾细胞癌）7 项研究
- 心力衰竭7 项研究
- 转移性癌症7 项研究
- 结直肠癌7 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。